百濟神州(06160.HK)將在ASCO年會上展示豐富且成熟的腫瘤學藥物組合臨牀數據
格隆匯5月27日丨百濟神州(06160.HK)2022年5月27日宣佈，公司將在當地時間2022年6月3日至6月7日於芝加哥舉行的美國臨牀腫瘤學會(ASCO)年會上展示其豐富的實體瘤和血液腫瘤藥物組合中的8項研究數據報吿。
此次展示的數據重點包括BTK抑制劑百悦澤®(澤布替尼)的最新臨牀數據：百悦澤®對比伊布替尼用於治療華氏巨球蛋白血癥患者的3期ASPEN臨牀試驗的長期安全性和有效性結果，中位隨訪時間為43個月 ；百悦澤®聯合奧妥珠單抗對比奧妥珠單抗單藥治療復發╱難治性濾泡性淋巴瘤患者的2期ROSEWOOD臨牀試驗的主要分析結果。
百濟神州全球研發負責人汪來博士表示：“華氏巨球蛋白血癥是一種慢性、惰性的血液惡性腫瘤，患者的中位生存期可能長達14至16年。因此，對於這些需要長時間治療的患者而言，瞭解治療方案的長期特徵至關重要。在ASPEN試驗的長期隨訪過程中，百悦澤®展現出了持久的疾病緩解及安全性優勢，進一步增強了我們對其安全性和有效性的信心。我們將繼續探索百悦澤®在其他適應症中的使用，從而為更多患者提供可耐受、有效的全新治療選擇。同時，百悦澤®的2期 ROSEWOOD試驗在高風險、復發╱難治性的濾泡性淋巴瘤患者中取得了積極結果，對此我們也深受鼓舞。”
除了公佈百悦澤®最新臨牀試驗結果，百濟神州還將在6月5日的摘要更新會議上對其早期開發管線以及百澤安® (替雷利珠單抗)3期臨牀試驗RATIONALE 309的結果進行海報展示。RATIONALE 309是一項3期臨牀試驗，評估百澤安®聯合化療對比安慰劑聯合化療，用於一線治療復發或轉移性鼻咽癌患者的效果。這些結果已在2022年4月19日的ASCO全體大會系列會議上進行了初步展示：百濟神州公佈3期臨牀試驗RATIONALE-309的更新結果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
